SRR1421177
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.437
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.435
- SPERMATOGENESIS+0.278
- KRAS_SIGNALING_DN+0.241
- PEROXISOME+0.148
- FATTY_ACID_METABOLISM+0.137
- HEME_METABOLISM+0.125
- PANCREAS_BETA_CELLS+0.107
- UV_RESPONSE_DN+0.086
- PROTEIN_SECRETION+0.062
Top 10 suppressed
- TGF_BETA_SIGNALING-0.546
- NOTCH_SIGNALING-0.442
- WNT_BETA_CATENIN_SIGNALING-0.419
- TNFA_SIGNALING_VIA_NFKB-0.410
- ALLOGRAFT_REJECTION-0.376
- E2F_TARGETS-0.367
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.354
- G2M_CHECKPOINT-0.352
- MYC_TARGETS_V2-0.346
- INFLAMMATORY_RESPONSE-0.345
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1402900 | GTEX | — | 0.935 |
| 2 | SRR1468514 | GTEX | — | 0.933 |
| 3 | SRR1420984 | GTEX | — | 0.907 |
| 4 | SRR1387809 | GTEX | — | 0.903 |
| 5 | SRR1101421 | GTEX | — | 0.901 |
| 6 | SRR1082262 | GTEX | — | 0.893 |
| 7 | SRR1435775 | GTEX | — | 0.891 |
| 8 | SRR1336660 | GTEX | — | 0.890 |
| 9 | SRR807591 | GTEX | — | 0.890 |
| 10 | SRR1311086 | GTEX | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.437 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.435 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.278 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.241 | Remibrutinib | — uncovered |
| PEROXISOME | 0.148 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.137 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.125 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.107 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.086 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.062 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.048 | Inavolisib | — uncovered |
| MYOGENESIS | 0.046 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.037 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.028 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.022 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.019 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.004 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.003 | Inavolisib | — uncovered |